Movement Alert｜Liquidia Technologies Rises 5.18% in Regular Trading, Trading at $74.64

Market Focus06-23

On June 23, Liquidia Technologies rose 5.18% in regular trading, trading at $74.64/share, with Turnover of $73.327 million. The stock surpassed its prior 52-week high of $73.22, reaching a new all-time high.

Within the Pharmacy sector where Liquidia Technologies belongs, individual stock performance was mixed. Among individual stocks, Definium Therapeutics up 50.82%, Novo-Nordisk up 7.35%, Eli Lilly up 1.38%, Johnson & Johnson up 1.16%, Pfizer down 0.42%.

Liquidia Corporation is a biopharmaceutical company focused on pulmonary arterial hypertension (PAH) treatment. Its lead product candidate YUTREPIA is an inhaled dry powder formulation of treprostinil for PAH and pulmonary hypertension associated with interstitial lung disease. The company also offers Remodulin and holds a license agreement for L606, an inhaled sustained-release formulation of Treprostinil.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167203944?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 00:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167203944","market":"us","top_or_hot":-1,"title":"Movement Alert｜Liquidia Technologies Rises 5.18% in Regular Trading, Trading at $74.64","media":"Market Focus","content":"<p><p>On June 23, Liquidia Technologies rose 5.18% in regular trading, trading at $74.64/share, with Turnover of $73.327 million. The stock surpassed its prior 52-week high of $73.22, reaching a new all-time high.</p><p>Within the Pharmacy sector where Liquidia Technologies belongs, individual stock performance was mixed. Among individual stocks, Definium Therapeutics up 50.82%, Novo-Nordisk up 7.35%, Eli Lilly up 1.38%, Johnson & Johnson up 1.16%, Pfizer down 0.42%.</p><p>Liquidia Corporation is a biopharmaceutical company focused on pulmonary arterial hypertension (PAH) treatment. Its lead product candidate YUTREPIA is an inhaled dry powder formulation of treprostinil for PAH and pulmonary hypertension associated with interstitial lung disease. The company also offers Remodulin and holds a license agreement for L606, an inhaled sustained-release formulation of Treprostinil.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Liquidia Technologies Rises 5.18% in Regular Trading, Trading at $74.64</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Liquidia Technologies Rises 5.18% in Regular Trading, Trading at $74.64\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-23 00:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 23, Liquidia Technologies rose 5.18% in regular trading, trading at $74.64/share, with Turnover of $73.327 million. The stock surpassed its prior 52-week high of $73.22, reaching a new all-time high.</p><p>Within the Pharmacy sector where Liquidia Technologies belongs, individual stock performance was mixed. Among individual stocks, Definium Therapeutics up 50.82%, Novo-Nordisk up 7.35%, Eli Lilly up 1.38%, Johnson & Johnson up 1.16%, Pfizer down 0.42%.</p><p>Liquidia Corporation is a biopharmaceutical company focused on pulmonary arterial hypertension (PAH) treatment. Its lead product candidate YUTREPIA is an inhaled dry powder formulation of treprostinil for PAH and pulmonary hypertension associated with interstitial lung disease. The company also offers Remodulin and holds a license agreement for L606, an inhaled sustained-release formulation of Treprostinil.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"","article_id":"1167203944","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167203944","pubTimestamp":1782147034,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 23, Liquidia Technologies rose 5.18% in regular trading, trading at $74.64/share, with Turnover of $73.327 million. The stock surpassed its prior 52-week high of $73.22, reaching a new...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc"},"translate_title":"走势提示|Liquidia Technologies常规交易上涨5.18%，报74.64美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":1},"content_text":"On June 23, Liquidia Technologies rose 5.18% in regular trading, trading at $74.64/share, with Turnover of $73.327 million. The stock surpassed its prior 52-week high of $73.22, reaching a new all-time high.Within the Pharmacy sector where Liquidia Technologies belongs, individual stock performance was mixed. Among individual stocks, Definium Therapeutics up 50.82%, Novo-Nordisk up 7.35%, Eli Lilly up 1.38%, Johnson & Johnson up 1.16%, Pfizer down 0.42%.Liquidia Corporation is a biopharmaceutical company focused on pulmonary arterial hypertension (PAH) treatment. Its lead product candidate YUTREPIA is an inhaled dry powder formulation of treprostinil for PAH and pulmonary hypertension associated with interstitial lung disease. The company also offers Remodulin and holds a license agreement for L606, an inhaled sustained-release formulation of Treprostinil.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167203944","isCrawlerRequest":true}